EMERYVILLE, Calif., June 23,
2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq:
AMRS), a leading synthetic biotechnology company accelerating the
world's transition to sustainable consumption through its
Lab-to-Market™ technology platform today announced that it has
successfully started fermentation at its new precision fermentation
plant in Barra Bonita, Brazil.
The greenfield site at Barra Bonita establishes Amyris as the
leading manufacturer of highly engineered organisms at industrial
scale. The first of its kind precision fermentation plant is a
strategic investment made to meet rapidly growing demand for clean,
sustainable, chemistry-based products for the beauty, personal
care, health and wellness markets.
The plant consists of five precision fermentation
"mini-factories" capable of concurrently producing all 13 of
Amyris' molecules currently in the market as well as future
bio-fermented products. The plant's capacity is fully committed
through the end of 2023 with the production of natural vanillin,
sugarcane-based Reb M, squalane, squalene, hemisqualene and
patchouli along with other molecules. The plant will allow Amyris
to more efficiently meet demand from its ingredient customers after
several years of operating under third-party capacity supply
constraints.
"The commissioning and start-up of our Barra Bonita facility is
a significant milestone for Amyris. I am very proud of the team
that has engineered and constructed our new plant in record time
and during an unprecedented pandemic," said Eduardo Alvarez, Chief Operating Officer of
Amyris. "Our team has delivered the world's leading precision
fermentation facility for producing natural products using highly
engineered organisms. Over 800 people have played an important role
in the successful execution of this project. We are very pleased to
be operating this state-of-the-art in-house manufacturing facility
enabling us to more efficiently respond to customer demand in the
future."
About Amyris
Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology
company, transitioning the Clean Health & Beauty and Flavors
& Fragrances markets to sustainable ingredients through
fermentation and the company's proprietary Lab-to-Market™
technology platform. This Amyris platform leverages
state-of-the-art machine learning, robotics and artificial
intelligence, enabling the company to rapidly bring new innovation
to market at commercial scale. Amyris ingredients are included in
over 20,000 products from the world's top brands, reaching more
than 300 million consumers. Amyris also owns and operates a family
of consumer brands that is constantly evolving to meet the growing
demand for sustainable, effective and accessible products. For more
information, please visit http://www.amyris.com.
Amyris, the Amyris logo and Lab-to-Market are trademarks or
registered trademarks of Amyris, Inc. in the U.S. and/or other
countries.
Forward-Looking
Statements
This release contains forward-looking statements, and any
statements other than statements of historical fact could be deemed
to be forward-looking statements. These forward-looking statements
include, among other things, statements regarding future events,
such as Amyris' ability to meet growing customer demand through its
new Barra Bonita plant and Amyris' expectation regarding production
capacity and commitments through 2023. These statements are based
on management's current expectations and actual results and future
events may differ materially due to risks and uncertainties,
including risks related to Amyris' liquidity and ability to fund
operating and capital expenses, risks related to its financing
activities, risks related to potential delays or failures in
completing and integrating planned acquisitions, risks related to
potential delays or failures in development, regulatory approval,
launch, production and commercialization of products, risks related
to the COVID-19 pandemic and any other geopolitical events,
including Russia's invasion of Ukraine, resulting in
global economic, financial and supply chain disruptions that may
negatively impact Amyris' business operations and financial results
or cause market volatility, risks related to Amyris' reliance on
third parties particularly in the supply chain, and other risks
detailed from time to time in filings Amyris makes with the
Securities and Exchange Commission, including Annual Reports on
Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on
Form 8-K. Amyris disclaims any obligation to update information
contained in these forward-looking statements, whether as a result
of new information, future events, or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/amyris-barra-bonita-fermentation-plant-begins-industrial-production-301573994.html
SOURCE Amyris, Inc.